Charles River Partners with Lilly on TuneLab Platform

Charles River Laboratories announced a strategic collaboration with Eli Lilly and Company to incorporate nonclinical testing services into Lilly's TuneLab platform. The partnership seeks to standardize testing protocols across organizations, potentially accelerating drug development.

Details

Under the agreement, Charles River will integrate its nonclinical testing services into TuneLab, a digital platform developed by Lilly for trial data management. Financial terms were not disclosed.

Context

The partnership comes as pharmaceutical companies seek to standardize preclinical testing and reduce variability. Charles River brings extensive experience in nonclinical testing, while Lilly provides a sophisticated digital platform.

What This Means for Investors

For Lilly (LLY) investors, the partnership could improve development efficiency and reduce costs over time. For Charles River, it expands service offerings and strengthens market position.